The Latest in CML

TFR achievable with second-line nilotinib for chronic CML

March 9, 2018

CML

FDA expands indication for bosutinib in newly diagnosed CML

January 2, 2018

CML

FDA updates nilotinib product label outlining criteria for discontinuation

December 27, 2017

CML

Cancer patients with TKI-induced hypothyroidism had better survival rates

November 15, 2017

FDA approves dasatinib for pediatric Ph+ CML

November 14, 2017

CML

TKI dose de-escalation feasible in CML with stable MMR

July 20, 2017

CML

High CD86+pDC counts may predict CML relapses

May 3, 2017

CML

VIDEO: Careful TKI hiatus makes CML pregnancy possible

April 8, 2017

CML

In CML, imatinib benefits persist at 10 years

March 8, 2017

CML

AML leads percent gains in 5-year survival among leukemias

January 30, 2017

VIDEO: Half-dose TKI safe, cost-effective in CML in stable remission

December 4, 2016

CML

Halving the TKI dose safe, cost effective in CML patients with stable remissions

December 4, 2016

CML

Secondary reference panel expands access for CML monitoring

November 10, 2016

CML

STIM1 long-term follow-up confirms imatinib discontinuation safety

October 13, 2016

CML

Cost may hinder timely TKI initiation for CML

October 7, 2016

CML